Assess whether scientific advice should be sought before the next trial

Situation

A competitor label that just got a narrower indication put pediatric investigation plan vs. disease epidemiology in front of pediatric-plan strategist in a biologics company planning a biosimilar pathway. This Pharma & Life Sciences / Pharmacovigilance close is scientific advice should be from pediatric investigation plan vs. disease epidemiology, and the live options are Proceed under protocol, Pause the pathway, Escalate safety review.

Decision

Pediatric-plan strategist in a biologics company planning a biosimilar pathway must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using pediatric investigation plan vs. disease epidemiology after a competitor label that just got a narrower indication.

Hypotheses to test

• Pediatric investigation plan vs. disease epidemiology reads as Proceed under protocol once a competitor label that just got a narrower indication is lined up to the same Pharma & Life Sciences population.
• Pediatric investigation plan vs. disease epidemiology is closer to Pause the pathway after a competitor label that just got a narrower indication; Proceed under protocol would over-claim this Pharmacovigilance extract.
• Escalate safety review is still live in pediatric investigation plan vs. disease epidemiology for pediatric-plan strategist in a biologics company planning a biosimilar pathway.
• Pediatric investigation plan vs. disease epidemiology is missing the fact pediatric-plan strategist needs after a competitor label that just got a narrower indication; stop this Pharma & Life Sciences close.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in pediatric investigation plan vs. disease epidemiology after a competitor label that just got a narrower indication.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on scientific advice should be.
• For this Pharma & Life Sciences Pharmacovigilance file, read pediatric investigation plan vs. disease epidemiology against a competitor label that just got a narrower indication and write the one fact that would move scientific advice should be for pediatric-plan strategist.

Recommendation